Technology

Tau Loop MR

Venous blood is carried throughout the left atrium, from the left ventricle to the aorta and throughout the body. When the left ventricle contracts, arterial blood is supplied to the aorta, and the mitral valve must be closed to prevent reflux to the ventricle. Mitral valve insufficiency (MR) is a phenomenon in which the mitral valve is not completely closed due to external factors or aging.

When mitral valve insufficiency (MR) occurs, respiratory failure, arrhythmia, and heart failure occur, and in severe cases, death.

The number of patients with mitral regurgitation increases rapidly after age 55, and is four times the number of patients with aortic valves. The catheter-based mitral regurgitation (MR) treatment market is estimated to reach a CAGR of 10%, reaching $ 2.1 billion USD (2.5 trillion KRW) in 2024 (2018 basis).

TR Croissant

Tricuspid regurgitation (TR) is one of the heart valve diseases. During the systolic phase of the right ventricle, three leaflets meet each other and during the process of closing the valve opening, a space is created due to incomplete closure, which causes blood to flow from the right ventricle back to the right atrium.

Functional/Secondary TR is a disease in which valve lobes or dry cuts are normal, but due to the expansion of the right atrium/right ventricle, the annular dilatation causes the valve lobes to not gather well and regurgitation occurs. It is known that functional tricuspid regurgitation accounts for 80 to 90% of patients with severe tricuspid regurgitation (Severe TR) who require treatment.

Tricuspid valve disease has been evaluated to have a somewhat lower importance of immediate treatment compared to other heart valve diseases (aortic valve, mitral valve). But, through recent clinical experience and numerous studies, it has been reported that tricuspid regurgitation significantly lowers the quality of life of patients and the mortality rate from the disease is also high.

The one-year mortality rate for patients with severe tricuspid regurgitation (Severe TR) reaches 30%, and the mortality rate is approximately 60% after 3 years.

Tricuspid regurgitation was a forgotten valve with little surgical treatment, but its importance has been re-examined recently, and it can be applied to patients who cannot undergo an operation if accessed through a catheter.

Recently, techniques that applied the treatment technology for mitral regurgitation to the tricuspid valve are being studied, and research results have been published that prove that the reduction of tricuspid regurgitation through a catheter leads to a decrease in mortality.